Alaunos Therapeutics, Inc. annual report, FY2017

Business context and reporting period

The supplied filing is Ziopharm Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, not a filing identified as Alaunos Therapeutics, Inc. The company describes itself as a clinical-stage biopharmaceutical developer of cancer immunotherapies, with Controlled IL-12 gene therapy and Sleeping Beauty engineered-cell therapy platforms. It had no product revenue; collaboration revenue was its only reported revenue.

Key financial metrics

FY 2017 cash used in investing activities was $0.7 million; financing activities provided $45.3 million, primarily from a May 2017 stock offering. Total liabilities were $58.4 million, including deferred revenue and derivative liabilities; the filing does not present a conventional debt balance. Operating margins are not meaningful given the absence of product sales and ongoing losses.

For Q4 2017, revenue was $1.6 million, operating expenses $15.0 million, operating loss $13.4 million, and net loss applicable to common stockholders $18.3 million (loss per share $0.12).

Material changes versus prior comparable period

• Revenue declined 7% year over year. FY 2017 revenue was primarily recognized under the Ares Trading collaboration.
• Reported R&D expense fell by $112.7 million, largely because 2016 included a $119.0 million noncash charge associated with Series 1 preferred stock. Excluding that charge, R&D expense increased by $6.3 million in 2017, reflecting higher staffing and cell- and gene-therapy program costs.
• G&A expense increased 3%. Net loss narrowed substantially, principally reflecting the prior-year noncash charge; preferred-stock dividends rose to $18.9 million from $7.1 million.
• Cash declined $10.1 million during 2017, compared with a $59.7 million decline in 2016, helped by the 2017 equity offering. Year-end cash was still below 2016’s level.

Outlook, commentary, risks and unusual items

• Management estimated available cash would fund operations into Q4 2018 and disclosed no committed additional financing. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern; further financing or partnerships would be needed, and failure to secure them could force program delays or cuts.
• Management anticipated initiating a randomized pivotal Phase 3 trial of Controlled IL-12 for recurrent glioblastoma in the second half of 2018, subject to regulatory approval and completion of manufacturing requirements. A Phase 1 combination study with nivolumab had begun in 2018; pediatric brain-tumor and Sleeping Beauty studies were also in development.
• Interim Phase 1 data reported median overall survival of 12.5 months among 15 recurrent-glioblastoma patients treated at the 20 mg veledimex dose, with mean follow-up of 11.1 months. This was preliminary, based on a small cohort, and compared with historical controls; it does not establish efficacy or predict pivotal-trial results.
• The company discontinued its graft-versus-host-disease program and returned related rights to Precigen to focus resources on oncology. It remained dependent on licensed technology and collaborators, including Precigen and MD Anderson.
• Series 1 preferred stock issued to Precigen carries monthly stock dividends, conversion and liquidation rights, and protective provisions. The stock dividends increased common-stock dilution exposure; the filing estimated 34.1 million common shares would result from conversion using a December 31, 2017 assumed conversion date.
• Other material risks include clinical and regulatory uncertainty, manufacturing and supply dependence, competition, intellectual-property and licensing risks, and the need for substantial additional capital. The company reported no material legal proceedings as of year-end and effective disclosure controls and internal control over financial reporting.

Most important facts to verify

• Confirm the issuer and filing identity: the source is Ziopharm Oncology, Inc., whereas the request metadata names Alaunos Therapeutics, Inc.
• Check subsequent financing, cash runway, and any developments affecting the going-concern assessment.
• Verify the status and timing of the planned Phase 3 glioblastoma trial, regulatory requirements, and manufacturing readiness.
• Review later, mature clinical data and trial design before drawing conclusions from the small interim survival cohort.
• Assess the terms, accrued dividends, conversion mechanics, and potential dilution of Series 1 preferred stock, along with material collaboration and license obligations.